Immune treatment company Therapeutics Solution International Inc (OTC Markets:TSOI) revealed on Wednesday a publication from the University of Miami, demonstrating intravenous administration of JadiCells results in a significant survival improvement in COVID-19 patients.
The company added that the JadiCell stem cells used for treating brain injury significantly increased the survival of COVID-19 patients in double Blind FDA Clinical Trial. The 24 patients clinical trial validated superior anti-inflammatory and regenerative properties of JadiCell.
Under the Phase 1/2 double blind, placebo-controlled trial, the company treated 12 advanced COVID-19 patients with 100m JadiCells intravenously at days zero and three and 12 patients received placebo control. At 28 days 91% of JadiCell treated patients survived whereas only 42% of patients in the placebo group survived. There were no adverse effects associated with JadiCell administration.
According to the company, the JadiCells are a type of "supercharged" mesenchymal stem cells which have been demonstrated by the company, as well as independent academic and private institutions to possess superior therapeutic activity as compared to other stem cells.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML